GHR is partnering boldly as we work to address the long-term effects of the COVID-19 pandemic on our partners and communities. Via a $1 million gift, the Foundation joins the Bill & Melinda Gates Foundation, Mastercard Impact Fund and Wellcome in supporting a collaborative effort to research, develop and bring effective COVID-19 treatments to market quickly and accessibly.
Building off the momentum across public and private sectors to achieve optimal outcomes for therapeutic solutions, the COVID-19 Therapeutics Accelerator (CTA) aims to fill gaps in the R&D ecosystem, remove barriers to drug development and scale up treatments to address the pandemic, particularly in low-resource settings. CTA is committed to equitable access, ensuring that supported innovations are available and affordable to all.
The immediate focus of this initiative is to develop therapies that mitigate the impact of COVID-19 and can be made available within this year, while leaving a sustainable infrastructure in place for the long term, ensuring future epidemic and pandemic preparedness.
Building off the momentum across public and private sectors to achieve optimal outcomes for therapeutic solutions, the COVID-19 Therapeutics Accelerator (CTA) aims to fill gaps in the R&D ecosystem, remove barriers to drug development and scale up treatments to address the pandemic, particularly in low-resource settings. CTA is committed to equitable access, ensuring that supported innovations are available and affordable to all.
The immediate focus of this initiative is to develop therapies that mitigate the impact of COVID-19 and can be made available within this year, while leaving a sustainable infrastructure in place for the long term, ensuring future epidemic and pandemic preparedness.
RSS Feed
